Shanghai Yan’an Pharmaceutical Yangpu Co., Ltd. (hereinafter referred to as the “Company”) held the eighteenth meeting of the second board of directors on November 15, 2021. According to relevant laws, regulations, regulatory documents and the "Shanghai Yan’an Pharmaceutical Yangpu According to the “Articles of Association of a Limited Company” (hereinafter referred to as “Articles of Association”), as an independent director, after reviewing and supervising the company’s business activities and carefully studying the meeting materials, I will be independent, objective and fair. The independent opinions on the matters involved are as follows:
1. Independent opinions on reviewing the "Proposal on the Company's 2021 Restricted Stock Incentive Plan (Draft)"
The formulation of the "Company's 2021 Restricted Stock Incentive Plan (Draft)" complies with the "Company Law", "Securities Law", and "Guidelines for the Supervision of Non-listed Public Companies No. 6-Supervisory Requirements for Equity Incentives and Employee Stock Ownership Plans (for Trial Implementation) "" and other relevant laws, regulations and normative documents, as well as the "Articles of Association".
The company's implementation of the equity incentive plan can further establish and improve the company's long-term incentive mechanism, attract and retain outstanding talents, fully mobilize the subjective initiative and creativity of the company's directors, senior managers, and core employees, and realize the company's interests, shareholders' interests and individual operators The long-term effective combination of interests does not damage the interests of the company and all shareholders.
I agree to the "Proposal on Reviewing the Company's 2021 Restricted Stock Incentive Plan (Draft)", and agree to submit the proposal to the general meeting of shareholders for deliberation.

Independent Director: Chen Daofeng

Shanghai Yan'an Pharmaceutical Yangpu Co., Ltd.
Board of Directors
November 16, 2021